key: cord-0899302-caq4ugmh
authors: Kantsadi, Anastassia L.; Vakonakis, Ioannis
title: Rapid assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy
date: 2020-06-17
journal: bioRxiv
DOI: 10.1101/2020.06.17.156679
sha: 98565e19b24749a82faa8de1812fc4866e807bde
doc_id: 899302
cord_uid: caq4ugmh

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of the coronavirus disease 2019, for which no effective therapeutics are available. The SARS-CoV-2 main protease (Mpro) is essential for viral replication and constitutes a promising therapeutic target. Recently, crystallographic fragment screening uncovered a large number of molecules binding at the Mpro active site as well as at sites of potential allostery. However, no information on fragment affinity is available. Here, we describe an efficient protocol for screening chemical compounds for binding to Mpro using saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy. We characterised the relative affinity of Mpro-binding fragments using STD-NMR, revealing a ~200-fold difference in binding potential. Combined with crystallographic structures of these fragments bound to Mpro, this information can assist ongoing drug design efforts.

Infections by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have resulted in 27 over 400,000 deaths as of early June 2020 (1) and led to the coronavirus 2019 (COVID-19) pandemic 28

(2-4). SARS-CoV-2 is a zoonotic betacoronavirus highly similar to SARS-CoV-1 and MERS-CoV, which 29 caused outbreaks in 2002 and 2012, respectively (5-7). Much of SARS-CoV-2 biology has been 30 described thus far by analogy to previously studied coronaviruses, including SARC-CoV-1 and MERS-31

CoV. SARS-CoV-2 encodes its proteome in a single, positive-sense, linear RNA molecule of ~30 kb 32 length, the majority of which (~21.5 kb) is translated into two polypeptides, pp1a and pp1ab, via 33 ribosomal frame-shifting (8, 9) . Key viral enzymes and factors, including most proteins of the reverse-34 transcriptase machinery, inhibitors of host translation and molecules signalling for host cell survival, 35 are released from pp1a and pp1ab via post-translational cleavage by two viral cysteine proteases (10). 36

These proteases, a papain-like enzyme cleaving pp1ab at three sites, and a 3C-like protease cleaving 37 the polypeptide at 11 sites, are primary targets for the development of antiviral drugs. 38

The 3C-like protease of SARS-CoV-2, also known as the viral main protease (M pro ), has been the 39 target of intense study owing to its centrality in viral replication. M pro studies have benefited from 40 previous structural analyses of the SARC-CoV-1 3C-like protease and the development of putative 41 inhibitors (11) (12) (13) (14) . The active sites of these proteases are highly conserved, and at least one family of 42 SARS-CoV-1 3C-like protease inhibitors, comprising peptidomimetic -ketoamides, has been shown to 43 be effective against M pro , thereby offering a promising lead for antiviral development (15). However, 44 to date no M pro -targeting inhibitors have been validated in clinical trials. Recently, structures of M pro 45 in complex with 74 fragments were resolved as part of a high-throughput screening using X-ray 46 crystallography (16). Hits included covalently and non-covalently bound molecules targeting the 47 protease active site, as well as the M pro dimerisation interface and surface epitopes. These structures 48 offer opportunities for the development of potent compounds that would directly inhibit M pro activity 49 or allosterically regulate it, for example by disrupting M pro dimerisation, which is known to reduce 50 activity of coronavirus 3C-like proteases (17). However, crystallographic structures of protein -ligand 51 complexes are silent on compound affinities, which is key information to select the most promising 52 leads. Further, the combined high concentration of protein (solid crystals) and of compounds (50 mM 53 typical) in crystallographic fragment screening assays raises the possibility that some very weak 54 binders may have been selected, which could lead inhibitor development towards blind alleys. 55

Here, we show that saturation transfer difference nuclear magnetic resonance (STD-NMR) 56 spectroscopy can rapidly assess compound binding to M pro . We use this method to derive the relative 57 affinities of non-covalent interactors identified by crystallographic fragment screening. This 58 information can aid selection of the most promising fragment 'hits' for further development. 59 60 61

Protein production and purification 63 A SARS-CoV-2 M pro genetic construct including the viral protease, a glutathione S-transferase N-64 terminal tag, and a C-terminal His6-tag (16) was transformed into E. coli strain Rosetta(DE3). 65

Transformed clones were pre-cultured at 37 °C in lysogeny broth supplemented with appropriate 66 antibiotics and grown to exponential phase for approximately 5 h. Starter cultures were used to 67 inoculate 1 L of Terrific Broth Autoinduction Media (Formedium) supplemented with 10% v/v glycerol 68 and appropriate antibiotics. Cell cultures were grown at 37 °C for 5 h and then cooled to 18 °C for 12 69 h. Bacterial cells were harvested by centrifugation at 5,000 x g for 15 min. 70

Cell pellets were resuspended in 50 mM trisaminomethane (Tris)-Cl pH 8, 300 mM NaCl, 10 mM 71 imidazole buffer, incubated with 0.05 mg/ml benzonase nuclease (Sigma Aldrich) and lysed by 72 sonication on ice. Lysates were clarified by centrifugation at 50,000 x g at 4 °C for 1 h. Lysate 73 supernatants were loaded onto a HiTrap Talon metal affinity column (GE Healthcare) pre-equilibrated 74 with lysis buffer. Column wash was performed with 50 mM Tris-Cl pH 8, 300 mM NaCl and 25 mM 75 imidazole, followed by protein elution using the same buffer and an imidazole gradient from 25 to 500 76 mM concentration. The His6-tag was cleaved using home-made recombinant human rhinovirus (HRV) 77 3C protease. The HRV 3C protease, His6-tag and further impurities were removed by a reverse HiTrap 78 and an excitation sculpting water-suppression scheme (19). Protein signal were suppressed in STD-92 6 complex points and 41.6 sec dwell time (12.02 kHz sweepwidth). Data were collected in an 94 interleaved pattern, with on-and off-resonance irradiation data separated into 16 blocks of 16 95 transients each (256 transients per irradiation frequency). Transient recycle delay was 4 sec and on-96 or off-resonance irradiation was performed using 0.1 mW of power for 3.5 sec at 0.5 ppm or 26 ppm, 97 respectively, for a total experiment time of approximately 45 minutes. Reconstructed time-domain 98 data from the difference of on-and off-resonance irradiation (STD spectra) or only the off-resonance 99 irradiation (reference spectra) were processed by applying a 2 Hz exponential line broadening function 100 prior to Fourier transformation. Phasing parameters were derived for each sample from the reference 101 spectra and copied to the STD spectra. 1 H peak intensities were integrated in TopSpin using a local- resonances, likely corresponding to methyl groups in the protein hydrophobic core, as well as down-126 field shifted resonances (>8.5 ppm) originating from hydrogen-bonded amides (Fig. 1A) . In addition to 127 demonstrating that M pro is folded under the conditions tested, these spectra allowed us to identify 128 multiple resonance frequencies where irradiation for STD-NMR experiments might be applied in a 129 protein-specific manner. 130

As the vast majority of compounds assessed feature aromatic groups (see below), we chose to 131 irradiate M pro at up-field shifted frequencies in STD-NMR experiments. Trials revealed that irradiation 132 at 0.5 ppm frequency produced unambiguous 1 H signals in STD spectra from ligands bound to M pro , 133 while simultaneously avoiding ligand excitation that would yield false-positive 1 H signals in the 134 absence of M pro (Fig. 1B) . Further, contributions of small molecules not binding to M pro , such as DMSO, 135

to the STD spectra were pseudo-dispersive in nature, due to imperfect signal subtraction, while true 136 ligands produced peaks in STD with absorptive 1 H lineshapes. We conclude that STD-NMR provides an 137 efficient method for detecting ligand binding to M pro . 138 139

To better evaluate the information provided by STD-NMR, we assessed using this method the 141 binding of compounds previously seen complexed to M pro in crystallographic fragment screening 142 experiments (16). As STD-NMR signal relies on ligand exchange between protein-bound and -free 143 states, we focused on non-covalent M pro interactors. 39 such compounds are part of the DSI-poised 144 fragment library to which we were given access, comprising 17 active site binders, two compounds 145 targeting the M pro dimerisation interface and 20 molecules binding elsewhere on the protein surface. 146

We initially recorded STD-NMR experiments in the absence of M pro to confirm that under these 147 conditions we obtained no or minimal STD signal from the ligands, and to verify ligand identity from 148 the reference 1 H spectra. Five ligands were either absent from our DSI-poised library or produced 149 reference 1 H spectra inconsistent with the compound chemical structure; these ligands were not evaluated further. Samples of 10 M M pro and 0.8 mM nominal ligand concentration were formulated 151 from the remaining 34 compounds, and STD-NMR spectra were recorded. The folded state of M pro in 152 the presence of each ligand was verified by collecting 1 H NMR spectra similar to that of Fig. 1A from 153 all samples ahead of STD-NMR experiments. 154

We observed large variation in 1 H STD signal intensity in the presence of M pro across ligands, with 155 many ligands producing little or no STD signal, suggesting substantial differences in compound affinity 156 for the protease (Table 1) . However, we also recorded up to ~15-fold differences in the per-1 H 157 integrated intensity of reference ligand spectra, indicating significant variation in ligand 158 concentrations in solution. Such concentration differences may arise from errors in sample 159 formulation or from concentration inconsistencies in the ligand library. To evaluate the former we 160 integrated the residual 1 H signal of deuterated DMSO in our reference spectra, which should have 161 been constant as DMSO was added alongside ligands in the samples, and found it to vary by less than 162 35% across any pair of samples (11% average deviation). Thus, although sample formulation did 163 introduce ligand concentration errors by up to ~1/3, the extend of these errors did not account for 164 the up to ~15-fold differences in relative ligand concentrations. 165

To factor in these concentration differences we calculated the STD amplification ratio (STDamp) 166 upon M pro binding for all compounds, which is related to ligand affinity. Strikingly, M pro binding varied 167 by ~200-fold across ligands ( Fig. 2A) , with the strongest interactions recorded for compounds x0434, 168 x0390, x1086 and x0195 (Table 1 ). Large differences in ligand affinity were also readily apparent by 169 incubating M pro with mixtures of two different compounds, where STD signal for only one compound 170 was visible (Fig. 2B ). We surmise that the relative affinities of small molecules towards M pro can be 171 readily assessed by STD-NMR, and that M pro -binding fragments identified by crystallography vary 172 substantially in their interaction affinities for this protease. Fragment-based screening is a tried and tested method for reducing the number of compounds 179 that need to be screened against a specific target in order to sample chemical space (21). Combined 180 with X-ray crystallography, which provides information on the target site and binding pose of ligands, 181

identified fragments are thought of as 'bricks' that, when combined, can yield potent and specifically-182 interacting compounds. However, crystallographic structures do not report on ligand affinity, and 183 obtaining fragment affinities is often difficult by biophysical methods, such as calorimetry, due to the 184 weak nature of these interactions. However, NMR methods, such as STD-NMR, provide highly 185 powerful and sensitive tools for identifying ligand binding to macromolecules, even when interaction 186 affinities are in the mM Kd range (22). Here, we showed that STD-NMR is a suitable method for 187 characterising the binding of fragments to M pro , an essential protease of SARC-CoV-2. 188

Despite its considerable molecular weight (~68 kDa dimer) and the low protein concentration (10 189 M) of samples in our study, M pro yielded 1 H NMR spectra of high quality and with strong signal/noise 190 in relatively little acquisition time (Fig. 1A) . Importantly, we observed no protein precipitation during high signal/noise STD data (Fig. 1B) , which suggests that further improvements in our protocol are 198 possible. For example, we anticipate that halving the amount of M pro used in 199 or reducing the experiment time to ¼ of its current duration, will still provide us with sufficient signal 200 to detect interacting compounds. Although we refrained from doing so in this study, as our goal was 201 to characterise the interaction of even weekly-binding M pro ligands, such modifications should be 202 considered if STD-NMR was used in a high-throughput manner to identify compounds binding to this 203 protease. 204

Our work showed that fragments identified by previous crystallography-based assays as binding to 205 M pro in a non-covalent manner (16) do so with a wide-range of relative affinities. Four ligands, x0195, 206 x0390, x0434 and x1086, were shown to be most promising on the basis of their M pro interaction 207 strength in solution. Of these, both x0195 and x0434 bind at the M pro active site (Fig. 2C) . However, 208 the x0196 and x0434 binding poses overlap only in part, with x0434 being in contact with the catalytic 209 cysteine residue and x0195 in the active site periphery. Thus, a likely direction towards the synthesis of a potent M pro inhibitor would be combining these two fragments, thereby exploiting a larger 211 fraction of the active site interface. 212

Interestingly, both x0390 and x1086 bind at the M pro surface at the junction between the protease 213 N-terminal catalytic subdomain and its C-terminal subdomain (Fig. 2D) . Previous work showed that 214 coronavirus 3C-like proteases are extensively regulated by the C-terminal subdomain, likely as this 215 subdomain enhances protease dimerisation that, in turn, increases catalytic activity by several fold 216 (23). The x1086 binding site locates proximal to the interface between the two M pro protomers; thus, 217 further development of this ligand holds potential for directly disrupting the M pro dimer and reducing 218 protease activity. However, x0390-derivatives may also yield means towards the allosteric control of 219 M pro , by altering the relative conformation of the catalytic and regulatory subdomains, thereby 220 impacting on protease function. 221

In conclusion, we presented here a protocol for the rapid assessment of SARS-CoV-2 M pro ligands 222 using STD-NMR spectroscopy and evaluated the relative affinities of fragments seen to bind this 223 protease. Although development of novel antivirals to combat COVID-19 is still at an early stage, we 224 hope that this information will prove valuable to groups working towards such treatments. 225 226 20.

DeLano WL. 

Early dynamics of 230 transmission and control of COVID-19: a mathematical modelling study

A new coronavirus associated with 233 human respiratory disease in China

A Novel Coronavirus from Patients with 235 Pneumonia in China

Severe respiratory 237 illness caused by a novel coronavirus

240 Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Isolation of a novel 243 coronavirus from a man with pneumonia in Saudi Arabia

Mechanisms and enzymes 245 involved in SARS coronavirus genome expression

The primary 247 structure and expression of the second open reading frame of the polymerase gene of the coronavirus 248 MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting 249 mechanism

From SARS to MERS: crystallographic studies on coronaviral proteases enable 251 antiviral drug design

Structure-based design, synthesis, 253 and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors

A structural view 256 of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters

The crystal structures of severe acute 259 respiratory syndrome virus main protease and its complex with an inhibitor

Design of wide-spectrum inhibitors targeting 262 coronavirus main proteases

Crystal structure of SARS-CoV-264 2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Crystallographic and 267 electrophilic fragment screening of the SARS-CoV-2 main protease

Evaluating the 3C-like protease 269 activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery

Characterization of Ligand Binding by Saturation Transfer Difference NMR 272 Spectroscopy

Water Suppression That Works -Excitation Sculpting Using Arbitrary 274 Wave-Forms and Pulsed-Field Gradients